Hailin Zheng

This inventor holds 24 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Organic Chemistry. Top assignee: Intra-Cellular Therapies, Inc.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hailin Zheng. Retrieved from https://idiyas.com/inventor/hailin-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 12)

% Patents Active = 95.8

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 16)

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 306(Granted Patents)

Location History:

Teaneck, NJ (US) (2017 - 2020)
New York, NY (US) (2014 - 2023)

Company Filing History:

24 out of 181

Intra-Cellular Therapies, Inc.

patents

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Organic Compounds

Pharmaceutical Compositions

Heterocycle Prodrugs

Phosphodiesterase Inhibitors

Pyrazolo Derivatives

Gamma Carboline

Tracers

Methods

1H-Pyrrolo Compounds

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331052 - Organic compounds (2025-06-17),

2. 12180210 - Compounds (2024-12-31),

3. 12173004 - Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs (2024-12-24),

4. 11773095 - Organic compounds (2023-10-03),

5. 11427587 - Organic compounds (2022-08-30),

6. 10561656 - Organic compounds (2020-02-18),

7. 10543194 - Organic compounds (2020-01-28),

8. 10300064 - Organic compounds (2019-05-28),

9. 10150774 - Compounds and methods (2018-12-11),

10. 10131671 - Organic compounds (2018-11-20),

11. 10105349 - Organic compounds (2018-10-23),

12. 10005789 - Organic compounds (2018-06-26),

13. 9938284 - Organic compounds (2018-04-10),

14. 9598426 - Organic compounds (2017-03-21),

15. 9556186 - Organic compounds (2017-01-31),

Title: Hailin Zheng: Innovator in Pharmaceutical Compounds

Introduction

Hailin Zheng is a distinguished inventor based in New York, NY, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 23 patents, Zheng is recognized for his innovative work that addresses critical medical challenges.

Latest Patents

Hailin Zheng's recent patent innovations include novel PDE2 inhibitory compounds, which are formulated for use as pharmaceuticals. These compounds hold promise for treating a variety of diseases. He has also contributed to the development of pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs. This invention specifically targets pathways involving the serotonin transporter and the dopamine receptor signaling system, which are vital in treating disorders related to these receptors.

Career Highlights

Zheng is currently employed at Intra-Cellular Therapies, Inc., where he has further honed his skills as an inventor and researcher. His work at this company involves the intersection of innovative chemistry and medical applications, pushing the boundaries of current pharmaceutical practices.

Collaborations

During his tenure, Hailin Zheng has collaborated with notable colleagues, including Peng Li and Lawrence P. Wennogle. These partnerships have strengthened the research environment at Intra-Cellular Therapies and fostered advancements in therapeutic solutions.

Conclusion

Hailin Zheng’s contributions to the pharmaceutical industry through his inventions and patents underscore his role as a key innovator. His work not only enhances the understanding of complex medical conditions but also paves the way for more effective treatments that can significantly benefit patients worldwide.

Profile summary based on public USPTO records.